The largest database of trusted experimental protocols

8 protocols using muramyl dipeptide mdp

1

Macrophage Immune Response Profiling

Check if the same lab product or an alternative is used in the 5 most similar protocols
Monocyte-derived macrophages (MDMs) were treated with muramyl dipeptide (MDP; Bachem, Torrance, CA), lipid A (Peptides International, Louisville, KY), Pam3Cys (EMD Millipore, Billerica, MA), polyI:C, flagellin, CL097, CpG (InvivoGen, San Diego, CA), IL23 (PeproTech), 10:1 multiplicity of infection Salmonella enterica serovar Typhimurium or adherent invasive Escherichia coli (AIEC) strain LF82. In some cases cells were incubated with neutralising anti-IL23p19 antibody (eBioscience, San Diego, CA) for 1 hour before the treatments. Supernatants were assayed for tumour necrosis factor (TNF), IL6, IL8, IL10 (BD Biosciences, San Jose, CA), IL1β or IL23 (coating antibody to IL23p19, clone eBio473P19, detection antibody to IL12/ IL23p40, clone C8.6) (eBioscience) by ELISA.
+ Open protocol
+ Expand
2

Generating Murine Bone Marrow-Derived Dendritic Cells and Macrophages

Check if the same lab product or an alternative is used in the 5 most similar protocols
BM single cell suspensions were cultured in complete RPMI 1640 media containing 20 ng/mL GM-CSF (PeproTech, Rocky Hill, NJ) (for BMDC) and 10% L929-conditioned medium (for BMM). Cultures were fed fresh medium every 3 days, and used at 6 to 8 days. Purity was >98% as assessed by flow cytometry. BMDC were CD11c+ and F4/80, while BMM were CD11b+, F4/80+ and CD11c. IFN-γ (PeproTech), muramyl dipeptide (MDP) (Bachem, King of Prussia, PA), and lipid A (Peptides International, Louisville, KY) were used in vitro.
+ Open protocol
+ Expand
3

Myeloid Cell Responses to Microbial Stimuli

Check if the same lab product or an alternative is used in the 5 most similar protocols
Myeloid-derived cells were treated with muramyl dipeptide (MDP) (Bachem, King of Prussia, Pennsylvania, USA), Pam3Cys-Ser-(Lys)4 (Calbiochem, La Jolla, California, USA), lipid A (Peptides International, Louisville, Kentucky, USA), flagellin, CL097, CpG, poly I:C, Tri-DAP (Invivogen, San Diego, California, USA) or Salmonella enterica serovar Typhimurium (S. typhimurium) at multiplicity of infection (MOI) 10:1. For antibody and inhibitor treatments, cells were incubated with IL-1Ra (IL-1R antagonist) (Genscript), anti-IL-18 receptor accessory protein (RAP) (R&D Systems), Ac-YVAD-Cho (YVAD), caspase-8 inhibitor II or TPL2 inhibitor (Calbiochem) 1 h prior to treatment. Supernatants were assayed for tumour necrosis factor (TNF)-α, IL-8, IL-10 (BD Biosciences), IL-23, IL-1β and IL-18 (eBioscience) by ELISA.
+ Open protocol
+ Expand
4

Measurement of Ocular Cytokine Levels

Check if the same lab product or an alternative is used in the 5 most similar protocols
Muramyl dipeptide (MDP) and mouse recombinant IL-1β were purchased commercially (Bachem, Torrance, CA and R&D Systems, Minneapolis, MN, respectively). IL-1Ra, IL-1α, and IL-1β protein levels were measured in whole eye homogenates using commercially available ELISA kits (R&D Systems) as per manufacturer’s instructions and previously reported (16 (link)).
+ Open protocol
+ Expand
5

Fluorescent Labeling of Immune Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
BrdU was purchased from Invitrogen, LPS from Sigma, Muramyl-di-peptide (MDP) from Bachem and TRITC dextran (155kDa) and Alexa Fluor 594 conjugated LPS (10kDa) from Molecular Probes.
+ Open protocol
+ Expand
6

Cytokine Response in Myeloid Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cultured myeloid cells were treated with muramyl dipeptide (MDP) (Bachem, King of Prussia, PA), Pam3Cys-Ser-(Lys)4 (Calbiochem, La Jolla, CA), lipid A (Peptides International, Louisville, KY), flagellin, CL097, CpG, poly I:C (Invivogen, San Diego, CA) or IL-18 (R&D Systems Inc.). MDM were incubated with neutralizing anti-IL-18RAP or anti-IL-18 antibodies (R&D Systems Inc.) 1h prior to stimulation. Supernatants were assayed for TNF-α, IL-8, IL-6, IL-10 (BD Biosciences), or IL-18 and IL-1β (eBioscience, San Diego, CA) by ELISA.
+ Open protocol
+ Expand
7

Differentiation and Stimulation of Bone Marrow-Derived Macrophages

Check if the same lab product or an alternative is used in the 5 most similar protocols
BMDMs were generated as previously described.23 (link)
Briefly, bone marrow from femurs and tibias of mice undergoing control or HFD regimens were grown for 7 days in DMEM containing Ladmac-conditioned supernatant. Differentiation medium was replaced with DMEM containing 10% FBS and 1% antibiotic-antimycotic on day 7. On day 8, full serum media was replaced with low serum media (0.1% FBS) 4 h before stimulation with various agonists. Appropriate differentiation of BMDMs was verified by expression of F4/80 and CD11b by flow cytometry. Muramyl dipeptide (MDP) was purchased from Bachem and ultrapure lipopolysaccharide (LPS) was procured from Invivogen.
+ Open protocol
+ Expand
8

Macrophage Polarization Regulation by Cytokines

Check if the same lab product or an alternative is used in the 5 most similar protocols
Monocyte-derived macrophages (MDMs) were cultured with muramyl dipeptide (MDP) (Bachem, Torrance, CA), recombinant IL-10, IL-4, IL-22 (R&D Systems) or TSLP (Peprotech). For inhibitor and neutralizing antibody treatments, cells were incubated with JAK inhibitor I (total JAK inhibitor), SD-1029 (JAK2 inhibitor) (Calbiochem, La Jolla, CA), tofacitinib (manufactured by Pfizer, NY, NY), neutralizing anti-IL-10 (5 µg/ml), anti-IL-4 (1 µg/ml; BD Biosciences, San Jose, CA), anti-IL-22 (1.25 µg/ml; Peprotech) or anti-TSLP (0.25 µg/ml; R&D Systems) antibodies 1h prior to treatment. Supernatants were assayed for IL-10 (BD Biosciences), or IL-1β, IL-4, IL-6, IL-8, IL-12, IL-1ra (eBioscience, San Diego, CA), IL-22 (Peprotech) or TSLP (R&D Systems) by ELISA.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!